FOLH1 and prostate cancer: integrated PSMA PET/CT with variables including prostate volume, BMI, the number of positive biopsy cores, and other indicators to develop a nomogram tool for prognosticating pathological upgrading in prostate cancer patients, resulting in enhanced predictive accuracy rates (18).